Reed Jobs, son of Steve Jobs, focuses on oncology at Yosemite, leveraging AI and new strategies for drug development.
Reed Jobs is no stranger to the pressures of legacy and expectation, being the son of the late Apple co-founder Steve Jobs. However, in a world where biotech is increasingly becoming the centerpiece of investment and startups-secure-434-7-million-in-second-quarter-driven-by-megadeals/">innovation, Reed is carving out his own identity as the founder of Yosemite, an oncology-focused venture firm. Established amidst the post-pandemic landscape, Yosemite aims to revolutionize cancer treatment while tapping into the burgeoning potential of artificial intelligence (AI) in drug development.
Since the firm’s inception in 2023, Reed Jobs has quickly transformed Yosemite from an ambitious startup to an emerging force in the biotech industry. Today, the firm employs a dedicated team of 17 experts and touts a diverse portfolio of companies that are exploring novel therapeutic approaches. As patent expirations loom over several blockbuster drugs, Jobs asserts that the timing for Yosemite’s unique business model is becoming increasingly favorable.
Reed Jobs maintains a clear focus on making Yosemite a significant player in the biotech industry. The firm operates under two guiding principles: focusing exclusively on oncology, which comprises 40% of the biotech market, and emphasizing the need to build new companies from the ground up.
During a recent interview, Reed discussed the current state of Yosemite following the announcement of their second fund, which targets $350 million. "We’ve had incredible traction and added many significant partners," he noted. While a third of the fund is allocated towards developing companies internally, the rest is directed toward established entities where Yosemite seeks to invest. This innovative approach allows the firm to mitigate risks associated with early-stage projects by leveraging philanthropy and strategic partnerships with leading academic institutions.
AI is at the forefront of Yosemite’s operational strategy, enabling faster and more efficient drug discovery and clinical trial management. Jobs believes that integrating AI into these processes will play a pivotal role in transforming cancer treatment. The firm is employing AI technology to access previously undrugged parts of the human genome, which offers new avenues for targeting stubborn diseases.
According to Jobs, traditional approaches to clinical trials are fraught with high costs and low success rates. For instance, he cited that a typical Phase 3 cancer trial costs around $260 million, with only a one in three chance of success. The potential for AI to streamline these trials by creating synthetic control arms—utilizing patient data to simulate control groups—presents a significant opportunity. Jobs remarked, "AI could halve the number of patients we need to recruit, dramatically increasing the speed and efficiency of trials. The FDA is already leaning into this innovative approach."
Yosemite is looking to break ground with several groundbreaking therapies. Among the ventures Jobs is particularly enthusiastic about are Azalea, a biotech firm originating from a grant to Jennifer Doudna’s lab, and Quarry, which employs novel therapeutic methodologies to tackle cancer at the molecular level.
Furthermore, the firm is actively pursuing research into what Jobs terms the “Achilles’ heel” of cancer—the p53 gene. This tumor suppressor gene is frequently mutated across various cancers, presenting an opportunity for targeted therapies that pursue either restoration or alteration of its function. Jobs explained, "When we figure out how to manipulate p53 effectively, it could represent a monumental shift in cancer treatment strategies."
Yosemite has grown to encompass around 25 companies across both funds, with its operations underlining a collaborative ethos. Jobs emphasizes the importance of maintaining their doors open for founders looking to engage with Yosemite. "We take a meritocratic approach in our evaluation process; it doesn’t matter who you are or what title you hold," he said. This open-door policy aims to attract varied talent and innovative concepts, irrespective of their background in academia or industry.
While Jobs acknowledges the intricacies involved in attracting big pharma investments due to shifting priorities, he encourages founders to remain adaptive and vigilant. “Big pharma is a crucial partner, but it's imperative to stay informed about which players in the industry are actively investing in your space since their interests can change rapidly.”
The biotech sector has faced significant fluctuations in recent years, particularly following a downturn that affected numerous investors and companies alike. Yet, Jobs believes the tide is turning, thanks to favorable conditions like better interest rates and an impending wave of acquisitions spurred by substantial cash reserves built during the pandemic. Jobs noted, "Pharma companies are currently eyeing the largest patent cliff in history, driving interest and activity in the sector. Major acquisitions, such as Eli Lilly's $7 billion purchase of Kelonia, are setting the pace for innovation and competition."
This changing landscape is propelling new discoveries, with treatments for previously intractable cancers like pancreatic cancer showing promising advancements. Revolution Medicines, for example, has achieved a remarkable doubling of the survival rate for pancreatic cancer from 12 to 24 months—an achievement that underscores the potential of collaborative momentum in the sector.
Reed Jobs has also been a vocal advocate for the National Institutes of Health (NIH) funding, which has significant implications for the future of biomedical research. Last year, he expressed concerns over proposed cuts to the NIH budget, which could stifle innovation and slow progress across the industry. Fortunately, bipartisan efforts in Congress led to significant rejections of drastic funding cuts, allowing essential research to continue.
Jobs highlights the critical need for aggressive funding to enhance research capabilities and therapeutic advancements. He argued, "I believe we should be increasing NIH funding to around $100 billion. The overall budget hasn’t significantly grown in a decade when adjusted for inflation, and it's crucial that we address this to encourage the next wave of breakthroughs in medicine."
The future for Reed Jobs and Yosemite holds significant promise as they navigate the evolving landscape of biotech. With increasing investments in AI-driven drug discovery and validation, there is a palpable excitement about the breakthroughs just over the horizon. Jobs anticipates that as they continue innovating and pushing boundaries, Yosemite will be instrumental in locating and addressing life's most substantial challenges through science, technology, and collaboration.
As the biotech landscape evolves, Jobs reflects on the lessons learned throughout his journey. The rapid progression of science reminds him that the urgency for innovation is more significant than ever, and the potential for breakthroughs is abundant.
With his focus on combating cancer and driving forward-thinking technologies, Reed Jobs is committed to making a meaningful impact for future generations—pushing the boundaries of what's possible in the life sciences and ensuring that pediatric oncology is within reach.
When asked about the emerging longevity industry, Jobs expressed both personal and professional interests. Although he finds the field fascinating, he also recognizes the complexities of aging from multiple scientific perspectives. He emphasized, "I think we need tailored solutions that address individual variations in aging rather than a single, catch-all approach to longevity."
As awareness grows around longevity as a sector, the challenge lies in finding scientific consensus on aging mechanisms. Jobs remains optimistic about the potential for advancements that could ultimately enhance healthcare and improve quality of life as it pertains to aging, shaping how future treatments evolve.
With the prospects of both Yosemite and the biotech sector steadily expanding, Reed Jobs embodies a new wave of innovative leadership that prioritizes scientific breakthroughs, collaborative efforts, and investing in the future of health. The intersection of technology and biomedical research stands as a beacon of hope for countless patients and advocates alike.
As biotech continues to be central to modern medicine, Yosemite's pioneering approach serves as a reminder that the best innovations often come from a blend of new ideas, strategic investments, and the passion to make a difference.